This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Blue Wolf Capital Partners LLC agreed to acquire Seven manufacturing and development facilities of Recipharm AB. CI
Synokem Pharmaceuticals Limited acquired 74% stake in Nitin Lifesciences Limited from Recipharm AB. CI
Recipharm Announces CEO Changes CI
Recipharm Appoints Marc Funk as Board of Directors CI
Recipharm Announces Executive Appointments CI
NewBiologix SA announced that it has received CHF 45 million in funding from Recipharm AB and other investors CI
Recipharm Appoints Vikas Gupta as President of ReciBioPharm CI
Recipharm Announces Chief Financial Officer Changes CI
RS BioTherapeutics Selects Recipharm as Product Characterization Partner CI
Recipharm AB acquired Arranta Bio Holdings, LLC from Ampersand Capital Partners and others. CI
Recipharm AB completed the acquisition of Vibalogics GmbH. CI
Arranta Bio Holdings, LLC agreed to acquire Recipharm AB from Ampersand Capital Partners and others. CI
Recipharm AB agreed to acquire Vibalogics GmbH. CI
Recipharm AB acquired GenIBET Biopharmaceuticals, S.A. CI
Recipharm Secures Vaccine Manufacturing Deal CI
Recipharm AB agreed to acquire Niche Pharmaceuticals Inc. CI
Pharmaron Beijing Co., Ltd. acquired Aesica Pharmaceuticals Limited from Recipharm AB. CI
Transcript : Recipharm AB - Special Call
Recipharm AB Announces First Customer Boards Recipharm's Soft Mist Inhaler Technology Platform CI
Recipharm Launches New Laboratory to Expand Analytical Services Offering CI
Recipharm AB Appoints Mr. Manivel Thangapragasam as Associate Director CI
Recipharm Invests in Fill Finish Capacity CI
Recipharm : Enters Deal to Operate Fill-Finish Factory in Morocco MT
Recipharm Signs Memorandum of Understanding for the Fill Finish of Vaccines and Biotherapeutics in Morocco CI
Moderna, Inc. and Recipharm Site in France Manufacturing Covid-19 Vaccine Moderna Following Approval by European Medicines Agency CI
Chart Recipharm AB (publ)
More charts
Recipharm AB (publ) is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). The Company's acivities are devided into four business segments: Advanced Delivery Systems, which develops and manufactures inhalation products and devices including integrated drug solutions, medical check valves and injection devices. Steriles, which manufactures sterile products, including the use of lyophilisation and blow-fillseal (BFS) technologies. Solids & Others, which manufactures non-sterile products, including tablets, capsules, semi-solids, liquids and powders but excluding inhalation products and Development & Licensing, which provides pharmaceutical development services, and manages Recipharm's patents, technologies, and drug product rights, as well as the development and manufacturing of drug substance (Active Pharmaceutical Ingredient, API). The Company operates worldwide.
More about the company
  1. Stock Market
  2. Equities
  3. RECI B Stock
  4. News Recipharm AB (publ)
  5. Recipharm : Nasdaq Stockholm Approves Recipharm's Delisting Request